• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于制造过继性细胞免疫疗法的生物反应器开发的最新进展

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies.

作者信息

Ganeeva Irina, Zmievskaya Ekaterina, Valiullina Aygul, Kudriaeva Anna, Miftakhova Regina, Rybalov Alexey, Bulatov Emil

机构信息

Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.

出版信息

Bioengineering (Basel). 2022 Dec 15;9(12):808. doi: 10.3390/bioengineering9120808.

DOI:10.3390/bioengineering9120808
PMID:36551014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9774716/
Abstract

Harnessing the human immune system as a foundation for therapeutic technologies capable of recognizing and killing tumor cells has been the central objective of anti-cancer immunotherapy. In recent years, there has been an increasing interest in improving the effectiveness and accessibility of this technology to make it widely applicable for adoptive cell therapies (ACTs) such as chimeric antigen receptor T (CAR-T) cells, tumor infiltrating lymphocytes (TILs), dendritic cells (DCs), natural killer (NK) cells, and many other. Automated, scalable, cost-effective, and GMP-compliant bioreactors for production of ACTs are urgently needed. The primary efforts in the field of GMP bioreactors development are focused on closed and fully automated point-of-care (POC) systems. However, their clinical and industrial application has not yet reached full potential, as there are numerous obstacles associated with delicate balancing of the complex and often unpredictable cell biology with the need for precision and full process control. Here we provide a brief overview of the existing and most advanced systems for ACT manufacturing, including cell culture bags, G-Rex flasks, and bioreactors (rocking motion, stirred-flask, stirred-tank, hollow-fiber), as well as semi- and fully-automated closed bioreactor systems.

摘要

利用人体免疫系统作为能够识别和杀死肿瘤细胞的治疗技术的基础,一直是抗癌免疫疗法的核心目标。近年来,人们越来越关注提高这项技术的有效性和可及性,使其广泛应用于过继性细胞疗法(ACT),如嵌合抗原受体T(CAR-T)细胞、肿瘤浸润淋巴细胞(TIL)、树突状细胞(DC)、自然杀伤(NK)细胞等多种细胞疗法。迫切需要用于生产ACT的自动化、可扩展、具有成本效益且符合GMP标准的生物反应器。GMP生物反应器开发领域的主要工作集中在封闭和全自动的即时护理(POC)系统上。然而,它们的临床和工业应用尚未充分发挥潜力,因为在复杂且往往不可预测的细胞生物学与精确性和全流程控制需求之间的微妙平衡存在诸多障碍。在这里,我们简要概述了用于ACT制造的现有和最先进的系统,包括细胞培养袋、G-Rex培养瓶以及生物反应器(摇摆式、搅拌瓶式、搅拌罐式、中空纤维式),还有半自动和全自动封闭生物反应器系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7978/9774716/113d63324d9c/bioengineering-09-00808-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7978/9774716/113d63324d9c/bioengineering-09-00808-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7978/9774716/113d63324d9c/bioengineering-09-00808-g001.jpg

相似文献

1
Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies.用于制造过继性细胞免疫疗法的生物反应器开发的最新进展
Bioengineering (Basel). 2022 Dec 15;9(12):808. doi: 10.3390/bioengineering9120808.
2
Establishing the scalable manufacture of primary human T-cells in an automated stirred-tank bioreactor.在自动化搅拌罐生物反应器中建立可扩展的原代人 T 细胞制造。
Biotechnol Bioeng. 2019 Oct;116(10):2488-2502. doi: 10.1002/bit.27088. Epub 2019 Jul 9.
3
Demonstrating the Manufacture of Human CAR-T Cells in an Automated Stirred-Tank Bioreactor.在自动化搅拌罐生物反应器中展示人源 CAR-T 细胞的制造。
Biotechnol J. 2020 Sep;15(9):e2000177. doi: 10.1002/biot.202000177. Epub 2020 Jul 12.
4
A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.一种基于质量源于设计的方法,用于提高对自动化搅拌罐生物反应器中CAR-T细胞生产过程的理解,并优化其生产和质量。
Front Immunol. 2024 Apr 9;15:1335932. doi: 10.3389/fimmu.2024.1335932. eCollection 2024.
5
Adoptive Immunotherapy beyond CAR T-Cells.过继性免疫疗法:超越嵌合抗原受体T细胞疗法
Cancers (Basel). 2021 Feb 11;13(4):743. doi: 10.3390/cancers13040743.
6
Automated Good Manufacturing Practice-compliant generation of human monocyte-derived dendritic cells from a complete apheresis product using a hollow-fiber bioreactor system overcomes a major hurdle in the manufacture of dendritic cells for cancer vaccines.使用中空纤维生物反应器系统从完整的外周血单个核细胞产品中自动化生成符合良好生产规范的人源单核细胞衍生树突状细胞,克服了癌症疫苗用树突状细胞生产的一个主要障碍。
Cytotherapy. 2019 Nov;21(11):1166-1178. doi: 10.1016/j.jcyt.2019.09.001. Epub 2019 Oct 23.
7
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.临床级、大规模、无饲养层扩增高活性人自然杀伤细胞,用于采用自动化生物反应器的过继免疫疗法。
Cytotherapy. 2010 Dec;12(8):1044-55. doi: 10.3109/14653249.2010.504770. Epub 2010 Aug 26.
8
Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.嵌合抗原受体结构以及使用不同生物反应器制造临床级嵌合抗原受体工程细胞
Hematol Oncol Stem Cell Ther. 2022 Nov 7;15(3):137-152. doi: 10.56875/2589-0646.1048.
9
Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor.使用计算机控制的搅拌罐生物反应器生产用于过继性免疫疗法的人类自然杀伤细胞。
J Hematother. 1996 Oct;5(5):475-83. doi: 10.1089/scd.1.1996.5.475.
10
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.用于原代人自然杀伤细胞临床规模制造及α逆转录病毒嵌合抗原受体工程的自动化分离、扩增和质量控制方案的开发。
Hum Gene Ther Methods. 2019 Jun;30(3):102-120. doi: 10.1089/hgtb.2019.039. Epub 2019 May 16.

引用本文的文献

1
Donor Variability and Seeding Density Shape NK-Cell Proliferation and Surface Receptor Expression: Insights from an Integrated Phenotypic and Genetic Analysis.供体变异性和接种密度塑造自然杀伤细胞增殖及表面受体表达:来自综合表型与基因分析的见解
Cells. 2025 Aug 14;14(16):1252. doi: 10.3390/cells14161252.
2
Strategies and delivery systems for cell-based therapy in autoimmunity.自身免疫性疾病中基于细胞治疗的策略与递送系统。
Front Drug Deliv. 2024 Aug 8;4:1436842. doi: 10.3389/fddev.2024.1436842. eCollection 2024.
3
Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy.

本文引用的文献

1
Manufacturing next-generation regulatory T-cell therapies.制造下一代调节性T细胞疗法。
Curr Opin Biotechnol. 2022 Dec;78:102822. doi: 10.1016/j.copbio.2022.102822. Epub 2022 Oct 27.
2
Impact of Manufacturing Procedures on CAR T Cell Functionality.制造工艺对 CAR T 细胞功能的影响。
Front Immunol. 2022 Apr 13;13:876339. doi: 10.3389/fimmu.2022.876339. eCollection 2022.
3
Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy.在搅拌式生物反应器中建立用于 CAR-T 细胞治疗的功能性慢病毒载体生产。
应对用于过继性细胞治疗的调节性T细胞在制造、测试及监管方面的复杂性。
Front Immunol. 2025 Jul 16;16:1626085. doi: 10.3389/fimmu.2025.1626085. eCollection 2025.
4
Large-Scale Expansion of Suspension Cells in an Automated Hollow-Fiber Perfusion Bioreactor.在自动中空纤维灌注生物反应器中大规模扩增悬浮细胞。
Bioengineering (Basel). 2025 Jun 12;12(6):644. doi: 10.3390/bioengineering12060644.
5
Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.颠覆 CAR T 细胞疗法:基因工程和制造创新,提高疗效和可及性。
Int J Mol Sci. 2024 Sep 26;25(19):10365. doi: 10.3390/ijms251910365.
6
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights.重塑未来:利用合成生物学、工程学和经济学的洞见,弥合 CAR T 细胞治疗的差距。
Front Immunol. 2024 Sep 5;15:1432799. doi: 10.3389/fimmu.2024.1432799. eCollection 2024.
7
Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development.靶向驱动的组织非特异性药物批准——药物研发的新途径。
Cancers (Basel). 2024 Jul 13;16(14):2529. doi: 10.3390/cancers16142529.
8
Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma.肝细胞癌治疗中的种族/民族差异与免疫治疗进展
Cancers (Basel). 2024 Jul 3;16(13):2446. doi: 10.3390/cancers16132446.
9
Promises and challenges of a decentralized CAR T-cell manufacturing model.分散式嵌合抗原受体T细胞制造模式的前景与挑战
Front Transplant. 2023 Sep 5;2:1238535. doi: 10.3389/frtra.2023.1238535. eCollection 2023.
10
Comparative Approaches for Quantification of Product Yield in a Model Recombinant Green Fluorescent Protein Expressed in .在……中表达的模型重组绿色荧光蛋白中产物产量定量的比较方法
bioRxiv. 2024 Jun 24:2024.06.24.600411. doi: 10.1101/2024.06.24.600411.
Bioengineered. 2021 Dec;12(1):2095-2105. doi: 10.1080/21655979.2021.1931644.
4
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.利弗利塞(一种肿瘤浸润淋巴细胞疗法)治疗转移性黑色素瘤。
J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12.
5
Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.生物反应器中的淋巴细胞扩增:提升过继性细胞疗法
J Biol Eng. 2021 Apr 13;15(1):13. doi: 10.1186/s13036-021-00264-7.
6
Adoptive Immunotherapy beyond CAR T-Cells.过继性免疫疗法:超越嵌合抗原受体T细胞疗法
Cancers (Basel). 2021 Feb 11;13(4):743. doi: 10.3390/cancers13040743.
7
Scale-Up Technologies for the Manufacture of Adherent Cells.用于贴壁细胞生产的放大技术。
Front Nutr. 2020 Nov 4;7:575146. doi: 10.3389/fnut.2020.575146. eCollection 2020.
8
A Comparison of Automated Perfusion- and Manual Diffusion-Based Human Regulatory T Cell Expansion and Functionality Using a Soluble Activator Complex.使用可溶性激活复合物对基于自动化灌注和手动扩散的人调节性 T 细胞扩增和功能进行比较。
Cell Transplant. 2020 Jan-Dec;29:963689720923578. doi: 10.1177/0963689720923578.
9
Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.使用封闭半自动生物反应器进行即时 CAR T 细胞生产(ARI-0001):来自学术性 I 期临床试验的经验。
Front Immunol. 2020 Mar 20;11:482. doi: 10.3389/fimmu.2020.00482. eCollection 2020.
10
Streamlined production of genetically modified T cells with activation, transduction and expansion in closed-system G-Rex bioreactors.在封闭式 G-Rex 生物反应器中进行激活、转导和扩增,实现基因修饰 T 细胞的简化生产。
Cytotherapy. 2019 Dec;21(12):1246-1257. doi: 10.1016/j.jcyt.2019.10.006.